These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1680 related articles for article (PubMed ID: 33294831)

  • 61. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
    Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
    Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
    Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models.
    Nachit M; De Rudder M; Thissen JP; Schakman O; Bouzin C; Horsmans Y; Vande Velde G; Leclercq IA
    J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):144-158. PubMed ID: 33244884
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

  • 66.
    Wang F; Liu S; Zhuang R; Bao J; Shen Y; Xi J; Sun J; Fang H
    Int J Clin Exp Pathol; 2018; 11(11):5351-5358. PubMed ID: 31949616
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The capsaicinoid nonivamide suppresses the inflammatory response and attenuates the progression of steatosis in a NAFLD-rat model.
    Wikan N; Tocharus J; Oka C; Sivasinprasasn S; Chaichompoo W; Suksamrarn A; Tocharus C
    J Biochem Mol Toxicol; 2023 Mar; 37(3):e23279. PubMed ID: 36541345
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
    Le TA; Loomba R
    J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1.
    Wu L; Liu Y; Zhao Y; Li M; Guo L
    Free Radic Biol Med; 2020 Jun; 153():140-158. PubMed ID: 32311490
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice.
    Bluemel S; Wang Y; Lee S; Schnabl B
    World J Gastroenterol; 2020 Sep; 26(33):4933-4944. PubMed ID: 32952340
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regulation of the macrophage-hepatic stellate cell interaction by targeting macrophage peroxisome proliferator-activated receptor gamma to prevent non-alcoholic steatohepatitis progression in mice.
    Ni XX; Ji PX; Chen YX; Li XY; Sheng L; Lian M; Guo CJ; Hua J
    Liver Int; 2022 Dec; 42(12):2696-2712. PubMed ID: 36165186
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.
    Jump DB; Depner CM; Tripathy S; Lytle KA
    Proc Nutr Soc; 2016 Feb; 75(1):1-9. PubMed ID: 26282529
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis.
    Zhao C; Ji G; Zhao X; Ma T; Li Y; Wu W; Zhou L
    Comb Chem High Throughput Screen; 2024 May; ():. PubMed ID: 38803181
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.
    Nagaya T; Tanaka N; Kimura T; Kitabatake H; Fujimori N; Komatsu M; Horiuchi A; Yamaura T; Umemura T; Sano K; Gonzalez FJ; Aoyama T; Tanaka E
    BBA Clin; 2015 Jun; 3():168-74. PubMed ID: 26674248
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
    Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
    Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-κB signaling pathway.
    Jiang B; Wang D; Hu Y; Li W; Liu F; Zhu X; Li X; Zhang H; Bai H; Yang Q; Yang X; Ben J; Chen Q
    Mol Metab; 2022 May; 59():101462. PubMed ID: 35247611
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lack of VMP1 impairs hepatic lipoprotein secretion and promotes non-alcoholic steatohepatitis.
    Jiang X; Fulte S; Deng F; Chen S; Xie Y; Chao X; He XC; Zhang Y; Li T; Li F; McCoin C; Morris EM; Thyfault J; Liu W; Li L; Davidson NO; Ding WX; Ni HM
    J Hepatol; 2022 Sep; 77(3):619-631. PubMed ID: 35452693
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH.
    Fredrickson G; Barrow F; Dietsche K; Parthiban P; Khan S; Robert S; Demirchian M; Rhoades H; Wang H; Adeyi O; Revelo XS
    Mol Metab; 2021 Nov; 53():101270. PubMed ID: 34118476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 84.